A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-12-10
Target enrollment:
Participant gender:
Summary
To assess safety and tolerability, describe the dose-limiting toxicities, assess the
preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest
protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and
a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or
metastatic solid tumor malignancies that have received at least 1 prior line of treatment.